Cart is empty 
Overview
Retatrutide (LY3437943) is a novel synthetic peptide investigated for its activity as a triple hormone receptor agonist targeting the Glucose-Dependent Insulinotropic Polypeptide (GIP), Glucagon-Like Peptide-1 (GLP-1), and Glucagon receptors. Research has focused on its effects on body weight regulation, glucose metabolism, energy expenditure, and metabolic health. The compound represents a next-generation multi-receptor incretin approach designed to influence multiple metabolic pathways simultaneously.
Mechanism of Action
Research suggests Retatrutide functions as a triple agonist of the GIP, GLP-1, and glucagon receptors. Activation of GLP-1 receptors may support glucose regulation and satiety signaling, GIP receptor activation may influence insulin sensitivity and metabolic function, while glucagon receptor activation may increase energy expenditure and fat oxidation. Studies have investigated its effects on body composition, weight regulation, and metabolic biomarkers.
Compound Information
Stability Information
- Type: Triple Receptor Agonist Peptide
- Development Code: LY3437943
- Targets: GIP, GLP-1, and Glucagon Receptors
- Category: Multi-Agonist Incretin Peptide
- Research Areas: Metabolism, body composition, energy expenditure, glucose regulation
- Room temperature stable (short-term)
- Protect from light
- Avoid repeated freeze-thaw cycles
- Lyophilized: Store at -20°C
- Reconstituted: Store at 2-8°C
Published Studies
- Retatrutide, a triple-hormone receptor agonist, for obesity treatment.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial.
- LY3437943: A Novel Triple GIP, GLP-1, and Glucagon Receptor Agonist.
- Pharmacological characterization of LY3437943 in preclinical models.
- Triple agonism improves body weight and metabolic markers in obesity models.
- Glucagon receptor activation and energy expenditure in obesity research.
- Multi-receptor incretin agonists and metabolic disease.
- GIP, GLP-1, and glucagon receptor co-agonism for obesity management.
- Advances in incretin-based therapies for obesity and metabolic disease.
- Emerging triple agonists targeting obesity and cardiometabolic disease.
Information provided for educational and research reference purposes only. Studies listed are third-party publications and do not constitute medical advice.